SplitMay 29, 2026, 07:06 AM
Silexion Therapeutics Completes 1-for-10 Reverse Share Split
AI Summary
Silexion Therapeutics Corp completed a 1-for-10 reverse share split, effective after the close of trading on May 28, 2026. The company's ordinary shares began trading on a split-adjusted basis on the Nasdaq Capital Market under the existing ticker symbol "SLXN" at market open on May 29, 2026. Concurrently, the company issued a notice to warrant holders, adjusting the number of shares issuable upon exercise and increasing the exercise price proportionally to $15,525.00 per post-Reverse Share Split ordinary share.
Key Highlights
- Silexion Therapeutics completed a 1-for-10 reverse share split, effective after market close on May 28, 2026.
- Ordinary shares began trading on a split-adjusted basis on Nasdaq under "SLXN" on May 29, 2026.
- Authorized share capital remains $796,500, now consisting of 5,900,000 ordinary shares.
- Par value of ordinary shares increased from $0.0135 to $0.135 per share.
- The number of ordinary shares issuable upon warrant exercise decreased to 1/10th of a share.
- The exercise price for each post-split warrant increased to $15,525.00 per ordinary share.
- Fractional shares from warrant exercise will be rounded up to the nearest whole number.
Price Impact
More from SLXN